BioSpace News Archive

Aquestive Therapeutics, Inc. announced a poster presentation highlighting the positive pharmacokinetic and pharmacodynamic data from two completed clinical studies for Anaphylm will be presented at the American Academy of Allergy, Asthma, and Immunology 2024 annual meeting, which will take place February 23-26 in Washington, D.C.

Fate Therapeutics, Inc. announced that the Company will host a conference call and live audio webcast on Monday, February 26, 2024 at 5:00 PM ET to report its fourth quarter and full year 2023 financial results and provide a corporate update.

Panbela Therapeutics, Inc., a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced that, has regained compliance with applicable listing standards of The Nasdaq Stock Market for bid price and publicly held shares.

Aurinia Pharmaceuticals Inc. provided an update on its 2023 fourth quarter and full year business performance, as well as a corporate update regarding the Company’s strategic review.

Amicus Therapeutics announced that the Company will host a conference call and live audio webcast on Wednesday, February 28, 2024, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2023.

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for rare diseases, reported business highlights and financial results for the fourth quarter and year ended December 31, 2023.

Renalytix plc, an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, reported financial results for the fiscal second quarter ended December 31, 2023.

Applied Therapeutics, Inc. announced positive interim 12-month results from the ongoing Phase 3 INSPIRE trial, in which the primary endpoints and several key secondary endpoints were achieved.

Compugen Ltd., a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024.

Labcorp, a global leader of innovative and comprehensive laboratory services, announced results for the fourth quarter and year ending Dec. 31, 2023, and full year 2024 guidance.